Overview

Methotrexate in Ankylosing Spondylitis (MTX in AS)

Status:
Unknown status
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Assessing the efficacy and tolerability of methotrexate 15mg sc in the first month of treatment- if well tolerated methotrexate 20mg sc in the following 3 months in patients with active anklyosing spondylitis
Phase:
Phase 2
Details
Lead Sponsor:
Charite University, Berlin, Germany
Treatments:
Methotrexate